VistaGen Therapeutics Inc (VTGN) - Total Liabilities
Based on the latest financial reports, VistaGen Therapeutics Inc (VTGN) has total liabilities worth $13.04 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check VistaGen Therapeutics Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
VistaGen Therapeutics Inc - Total Liabilities Trend (2008–2026)
This chart illustrates how VistaGen Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is VistaGen Therapeutics Inc's balance sheet.
VistaGen Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of VistaGen Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ZHONGLIANG HLDG HD-01
F:3ZH
|
Germany | €99.74 Billion |
|
Bermas SA
RO:BRM
|
Romania | RON15.28 Million |
|
Associate Global Partners Ltd
AU:APL
|
Australia | AU$5.24 Million |
|
HYDROGEN UTOPIA INT.-001
F:D60
|
Germany | €1.06 Million |
|
Zantat Holdings Berhad
KLSE:0301
|
Malaysia | RM28.33 Million |
|
Acme Holdings Bhd
KLSE:7131
|
Malaysia | RM94.22 Million |
|
Wong Engineering Corporation Bhd
KLSE:7050
|
Malaysia | RM54.95 Million |
|
PT Dafam Property Indonesia Tbk
JK:DFAM
|
Indonesia | Rp213.85 Billion |
Liability Composition Analysis (2008–2026)
This chart breaks down VistaGen Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of VistaGen Therapeutics Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how VistaGen Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for VistaGen Therapeutics Inc (2008–2026)
The table below shows the annual total liabilities of VistaGen Therapeutics Inc from 2008 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | $13.04 Million | -6.50% |
| 2025-03-31 | $13.95 Million | +48.94% |
| 2024-03-31 | $9.37 Million | +3.97% |
| 2023-03-31 | $9.01 Million | -9.26% |
| 2022-03-31 | $9.93 Million | -39.10% |
| 2021-03-31 | $16.30 Million | +41.74% |
| 2020-03-31 | $11.50 Million | +65.81% |
| 2019-03-31 | $6.94 Million | +59.03% |
| 2018-03-31 | $4.36 Million | +40.86% |
| 2017-03-31 | $3.10 Million | -21.95% |
| 2016-03-31 | $3.97 Million | -80.94% |
| 2015-03-31 | $20.81 Million | +59.32% |
| 2014-03-31 | $13.06 Million | -2.79% |
| 2013-03-31 | $13.44 Million | +122.22% |
| 2012-03-31 | $6.05 Million | +188875.00% |
| 2011-03-31 | $3.20K | +113.33% |
| 2010-03-31 | $1.50K | -44.15% |
| 2009-03-31 | $2.69K | +1019.17% |
| 2008-03-31 | $240.00 | -- |
About VistaGen Therapeutics Inc
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an od… Read more